U.S. pharma large copyright scrapped two experimental weight loss products final yr—a after-every day tablet, lotiglipron, as a result of elevated liver enzymes and also a two times-everyday pill, danuglipron, as a consequence of strong Unwanted effects—but CEO Albert Bourla has mentioned the company is determined to “Perform and acquire” w